Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Location
New York, NY
Fiscal year end
31 March
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 950% % -26%
Debt-to-equity 12% % 38%
Return On Equity -85% % -51%
Return On Assets -76% % -46%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 175,276,526 shares 19%
Common Stock, Shares, Outstanding 174,532,710 shares 19%
Entity Public Float $1,866,600,000 USD -14%
Common Stock, Value, Issued $17,000 USD 21%
Weighted Average Number of Shares Outstanding, Basic 173,643,829 shares 19%
Weighted Average Number of Shares Outstanding, Diluted 173,643,829 shares 19%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $83,493,000 USD 28%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $462,443,000 USD -43%
Income Tax Expense (Benefit) $2,243,000 USD 704%
Net Income (Loss) Attributable to Parent $464,686,000 USD -44%
Earnings Per Share, Basic -2 USD/shares -29%
Earnings Per Share, Diluted -2 USD/shares -29%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $521,870,000 USD 10%
Accounts Receivable, after Allowance for Credit Loss, Current $1,970,000 USD 5%
Assets, Current $573,546,000 USD 13%
Property, Plant and Equipment, Net $632,000 USD -5.8%
Operating Lease, Right-of-Use Asset $98,000 USD -26%
Other Assets, Noncurrent $8,781,000 USD 15%
Assets $582,959,000 USD 13%
Accounts Payable, Current $6,916,000 USD -67%
Accrued Liabilities, Current $50,748,000 USD 23%
Liabilities, Current $63,254,000 USD -5.1%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $63,254,000 USD -5.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,450,000 USD -24%
Retained Earnings (Accumulated Deficit) $1,486,638,000 USD -45%
Stockholders' Equity Attributable to Parent $519,705,000 USD 16%
Liabilities and Equity $582,959,000 USD 13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $117,411,000 USD -54%
Net Cash Provided by (Used in) Financing Activities $2,918,000 USD 325%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 174,532,710 shares 19%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $115,059,000 USD -53%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $521,870,000 USD 10%
Deferred Tax Assets, Valuation Allowance $218,753,000 USD 55%
Deferred Tax Assets, Gross $219,851,000 USD 55%
Operating Lease, Liability $138,000 USD -89%
Depreciation $107,000 USD 34%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $465,146,000 USD -44%
Lessee, Operating Lease, Liability, to be Paid $141,000 USD -89%
Operating Lease, Liability, Current $98,000 USD -29%
Lessee, Operating Lease, Liability, to be Paid, Year One $141,000 USD -88%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $3,000 USD -88%
Deferred Tax Assets, Operating Loss Carryforwards $153,370,000 USD 56%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,010,000 shares
Additional Paid in Capital $2,004,876,000 USD 36%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $1,098,000 USD 216%
Share-based Payment Arrangement, Expense $54,916,000 USD 19%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%